China
Africa
Explore chapters and articles related to this topic
Age-Related Macular Degeneration
Published in Ching-Yu Cheng, Tien Yin Wong, Ophthalmic Epidemiology, 2022
Jost B. Jonas, Songhomitra Panda-Jonas
As a disorder affecting probably first the retinal pigment epithelium (RPE), AMD is characterized in its early and medium advanced stage by structural and pigmentary irregularities of the RPE, including the formation of drusen as deposits beneath the RPE and above Bruch’s membrane.61 In addition, a detachment of the RPE may develop and subretinal drusenoid deposits may form. In the late stage of AMD, the RPE can get lost in the case of geographic atrophy and/or a fibrovascular scar with proliferation of the RPE can develop as a sequel of a choroidal neovascularization in the foveal region. These changes result in a central relative or absolute scotoma while the peripheral visual field is usually not affected. Since landmark clinical trials demonstrated in 2006 the therapeutic benefit of intravitreally applied antibodies against vascular endothelial growth factor (VEGF), repeated intravitreal injections of ranibizumab, bevacizumab, aflibercept, and conbercept significantly improved vision in treated patients compared to untreated patients in control groups.62–64 Correspondingly, recent population-based data have suggested that legal AMD-related blindness has been reduced by 50% in some countries since the introduction of VEGF antagonists.65,66
Corneal neovascularization inhibition and wound healing impregnability of conbercept on rabbit cornea after penetrating keratoplasty
Published in Cutaneous and Ocular Toxicology, 2022
Jianbin An, Yue Zeng, Huan Liu, Liying Huang, Jia Yao, Enchong Hou, Xiaorong Zhang
Both bevacizumab and Lucentis are early anti-VEGF antibody drugs and have been proved for their inhibitory effects on corneal neovascularization12. However, these drugs are single-target antagonists of neovascularization, and studies have shown that corneal epithelial changes or corneal thinning may be caused during the treatment, which limits the application of these drugs9. Conbercept is a novel anti-VEGF drug with multiple targets to block the signalling of new blood vessels. It has a strong affinity for VEGF-A, VEGF-B as well as PlGF, and has been used widely in the anti-angiogenesis treatment of fundus diseases13,14. However, there are few reports on the treatment of corneal neovascularization after PKP and other ocular surface neovascularization.
Updates on the Management of Ocular Vasculopathies with VEGF Inhibitor Conbercept
Published in Current Eye Research, 2020
Huan Liu, Yue Ma, Hong-Chang Xu, Li-Ying Huang, Li-Ying Zhai, Xiao-Rong Zhang
In the past decade, dramatic changes in the management of PDR and retinal vascular disease have been seen through the introduction of VEGF inhibitors. The first available anti-VEGF drug, pegaptanib, is a 28-nucleotide long aptamer, which binds to the VEGF-A 165 isomer.71 Preoperative intravitreal VEGF inhibitors have been widely applied currently. It has been proved that anti-VEGF treatment before vitrectomy decreases many complications and surgical procedures, including intraoperative bleeding, iatrogenic retinal breaks, early postoperative bleeding, the use of endo-diathermy, and duration of surgery.71–74 Currently three available VEGF antagonists, bevacizumab, ranibizumab, and aflibercept, have been developed and investigated in patients with PDR.71 Conbercept is a member of the anti-VEGF drugs. It was developed to provide a prolonged and more potent anti-VEGF effect.
Anti-VEGF agents in the management of diabetic macular edema
Published in Expert Review of Ophthalmology, 2020
Angela S. Li, Malini Veerappan, Vaishali Mittal, Diana V. Do
Conbercept (Chengdu Kanghong Biotech, Sichuan, China), a 143 kDa decoy receptor similar to aflibercept, is a fusion protein containing the second binding domain of VEGFR‐1 and the third and the fourth binding domains of VEGFR‐2. The fourth binding domain is not directly involved in ligand binding but rather induces dimerization of the antibody, which increases its binding affinity by over 100 fold [5]. Although no clinical trials have directly compared conbercept to laser for DME, a few retrospective studies have been done. One study in 2016 (n = 51) showed that intravitreal injections of conbercept with or without laser treatment resulted in improvements in both BCVA and central retinal thickness for patients with DME at 12 months of follow-up [77]. Another retrospective study in 2018 (n = 107) showed that intravitreal conbercept significantly improved BCVA and central macular thickness for patients with a variety of baseline visual acuities compared to corresponding controls [78]. Finally, a 2019 imaging study with 20 DME patients showed that conbercept treatment led to decreases in retinal edema; specifically, changes in the ganglion cell layer and the inner plexiform layer were associated with the most BCVA gain [79]. Both a Phase 1 (NCT01324869) and Phase 3 (NCT02194634) clinical trial studying the efficacy of conbercept in DME have been completed although the results have not yet been published.